Objective: Our goal was to conduct the generation and piloting of a discriminative and evaluative tool for pediatric post-thrombotic syndrome.
Introduction
Venous thromboembolic events are increasingly being reported in children (1) . This is in part due to the increased use of invasive diagnostic and therapeutic procedures, and the improvement of the detection methods for thrombotic events in modern medicine. As a consequence, venous thromboembolic events have become "the new epidemic" of hospitalized children (2) , affecting approximately 1 in 250 hospitalized patients (3).
Post-thrombotic syndrome (PTS) is the most frequent long-term complication of deep venous thrombosis (DVT) affecting the upper and lower extremities in children and adults (4) (5) (6) .
PTS is estimated to occur in 15 to 50% of adults affected by lower extremity (LE) deep vein thrombosis (7) , and 7 to 46% of adult patients after sustaining upper extremity (UE) deep vein thrombosis (8) . A systematic review of PTS in the pediatric population reported an overall frequency of 26% [95% Confidence Interval (CI): [23] [24] [25] [26] [27] [28] and a frequency of 17% [95% CI: [14] [15] [16] [17] [18] [19] [20] among prospective studies (9) , including both UE and LE venous territories.
It is well-established that PTS can lead to significant disability and poor quality of life in adult patients, particularly when complicated by skin ulcers (10) . The negative repercussion of PTS is largely due to its difficult, costly, and frustrating treatment (11, 12) .
The significance of PTS requires specific considerations in the pediatric population, since it is expected that the medical consequences of this syndrome will be disproportionately higher in younger patients (13) , who are anticipated to endure the sequelae of PTS for a longer period of time (14) . Nonetheless, the proper diagnosis and monitoring of PTS remains a difficult challenge in this young population.
A recent systematic review identified two outcome-assessment tools that are commonly used in pediatric patients: the Modified Villalta Scale and the Manco-Johnson Instrument (9) .
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Both were derived from tools used in adult patients and are the current reference instruments proposed by the International Society of Thrombosis and Hemostasis (ISTH) for the assessment of PTS in children (15) .
The Modified Villalta Scale derives from the Villalta Scale. The Villalta Scale (16, 17) was developed for the assessment of LE PTS in adults, since 96 to 99% of DVT occurring in adult patients affects the venous territory of the LE, whereas only 1 to 4% affects the UE (18) .
In striking contrast, 30 to 50% of cases of DVT in children affect the UE, thus highlighting the need for a pediatric tool that can be used to assess both UE and LE. For this reason, the original Villalta Scale was modified for use in pediatric patients by incorporating items (head edema, increase in limb circumference, and venous system collaterals), replacing the four-point scoring system used in the adult scale to indicate the severity of signs and symptoms with a dichotomous score (absent/present) for most items, and reducing the five symptoms measured by the Villalta Scale (pain, cramps, heaviness, paresthesia, and pruritus) to two symptoms: pain or abnormal use and swelling, to simplify its applicability in children of all ages (19) .
The Manco-Johnson Instrument (20) , adapted from a classification tool for chronic venous diseases in adults, the Clinical-Etiologic-Anatomic-Pathophysiologic (CEAP)
classification (21) , combines clinical signs (edema, collateral circulation, skin changes, and skin ulcer) and one symptom (pain). Pain is assessed with the Wong-Baker FACES Pain scale (22) and is evaluated at three different levels: rest, daily activities, and aerobic activities (15, 20) .
Both the Modified Villalta Scale and Manco-Johnson Instrument have been acknowledged to have limitations, which are mainly related to their measurement properties and the information they provide. The Pediatric PTS Task Force within the Pediatric and Neonatal
Hemostasis Subcommittee of the ISTH advocated for further investigation in order "to identify
[their] advantages and disadvantages" (15) .
One of the main shortcomings of these tools is the lack of operationalization of the items (i.e., signs and symptoms), since the tools do not clearly define all the items and do not always specify how the items should be measured.
Importantly, physicians caring for adult patients with chronic venous disorders, including PTS, have already recognized that the lack of consistent definitions of the terms used in venous diseases negatively impacts the comparison of clinical outcomes across studies and the exchange of medical information (23) , and can affect the reliability of the tools. To address this issue, an international and interdisciplinary group of experts in venous disorders developed several consensus documents, including the CEAP, revised CEAP, and VEIN-TERM consensus, which provided a common language for the reporting of chronic venous diseases (21, 23) .
In order to address the aforementioned limitations to the instruments currently used for the evaluation of pediatric PTS, we developed a new PTS assessment tool for this population.
The present study includes the steps of item generation and piloting. The latter stage served to investigate the diagnostic properties of the items obtained and their association (correlation) with PTS severity.
Methods
Underlying theory: The construct PTS was defined according to the literature as "chronic venous symptoms and/or signs secondary to DVT and its sequelae" (23, 24) . Therefore, PTS was considered to be defined precisely by the items (signs and symptoms) that are chosen to measure 25) . This conceptualization of the nature of the construct is one of the features of the formative model, and is consistent with the theory underlying the measurement of clinical phenomena (26) . Moreover, under the formative model, the items that define PTS are not expected to be interchangeable, but rather each item represents a different facet or aspect of PTS.
Conceptual framework: Given our focus on signs and symptoms, the construct PTS was mapped to the Body Functions and Structures component of the International Classification of Functioning, Disability and Health, Children and Youth Version (27) . Signs were defined as "visible manifestations of venous disorders", and symptoms as "complaints related to venous disease", as defined in the VEIN-TERM consensus (23).
Measurement purpose: The instrument was intended to be used for discriminative and evaluative purposes (i.e., to assess and monitor pediatric PTS) (28). above that of a homogeneous group (29) . Experts were asked to complete a survey by listing the signs and symptoms they considered should be measured to define and monitor UE and LE-PTS in children. The survey was designed using REDCap (Research Electronic Data Capture) software. To avoid introducing bias in the study by imposing
our views, we used open ended questions (30) . In view of the potential use of different terms by different respondents for items that were essentially the same and for subsequent item operationalization, the experts were asked to provide a brief description/meaning of the items and/or proposed measurement approach. The design and implementation of the survey followed the theory of social exchange to motivate participation (31) . Reminder emails and/or phone calls were used to enhance response rates.
b. Patient interview:
We conducted semi-structured interviews with school-aged children and teenagers who had sustained UE or LE-DVT before the age of 18 years, and who were subsequently diagnosed with mild to severe PTS by a pediatric thrombosis clinician. Patients <10 years of age were interviewed using a dyad-approach, in which the parent or proxy and the patient are interviewed at the same time. This approach has been reported to improve the assessment of health status in children, as compared to parent/proxy report alone (32) . In fact, we did not seek parent/proxy report alone, as the correlation between parent and child response has been shown to be low to moderate (32, 33) . Young adults no longer followed-up at our institution were interviewed over the phone. Patients with cognitive impairment or not fluent in English were not enrolled in the study.
1.2.
Sample size: Given the well-defined area of knowledge and the limited number of experts in the field, a sample size of at least 14 experts providing complete responses to the survey was considered adequate in the context of the study (34) . Patients were enrolled until reaching saturation (i.e., no new items were obtained), which usually entails between 5 and 25 patients, based on general guidelines for the conduction of qualitative studies using the phenomenological approach (35).
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Second phase: Item piloting
Under the formative model, each item (sign or symptom of PTS) captures a different aspect of the construct PTS. Hence, the challenge is to select the items that are most representative of the construct. To address this issue, we piloted the items obtained in the previous phase in a cohort of children at risk of PTS, and assessed the diagnostic performance of the signs and symptoms of PTS and their relationship with PTS severity. The resulting data will be evaluated by experts in the following phases of the study to select the items that, in their opinion, best represent the construct PTS.
For item piloting, we conducted a cross-sectional single-center study involving 1 to 21
year-old children with a history of objectively confirmed DVT, at least six months before the study procedures. Subjects with bilateral DVT, or with arterial thrombosis, muscular atrophy, active local inflammatory processes, or vascular malformations affecting the limb with the index DVT or the contralateral limb, were excluded to avoid confounding signs or symptoms. Patients with pacemakers were not enrolled since bioimpedance spectrospcopy, one of the techniques used to measure localized swelling (see below), is contraindicated in these patients.
2.1.
The signs and symptoms of PTS collected in phase 1 were measured as follows:
a. Symptoms of PTS were measured using a self-or proxy-reported questionnaire developed with all the items obtained in phase 1. The self-reported version was used for children aged 10 and older. The structure of the questionnaire followed that of the Edinburgh Vein Study (Prof. Gerry Fowkes, with permission). Three different tools were
used for the measurement of pain, according to the age of the patient: 1) Visual analogue scale using proxy/parental report for children 1-3 years. Marks were then translated into a 0-10 final score, reflective of the worst pain episode in the previous 4 weeks; 2) Faces Pain Scale-Revised (37) for patients aged ≥4 years. The choice was translated into a 0-10 final score, reflecting pain intensity over the previous 4 weeks; 3) Adolescent Pediatric
Pain Tool for patients aged ≥10 years. This tool includes a measure of pain intensity (translated into a 0-10 score), pain descriptors and distribution (38) . Only data on pain intensity was used in the present study. The proxy-reported questionnaire initially only included symptoms that we thought the parent/proxy would be able to observe. In addition, throughout the study, patients and proxies were inquired about other symptoms they thought should be included in the questionnaire.
b. Skin signs of PTS were measured using the items of the Venous Clinical Severity Score (39), namely skin pigmentation, skin inflammation, skin induration, and ulcers.
Additional skin signs were: skin discoloration (defined as reticulate erythema (40), erythema hyperemicum (41), and livedo reticularis (42)), trophic changes (defined as atrophy and lipoatrophy (40)), easy bruising (43), recurrent superficial infections/poor healing, and altered perfusion (44) . Skin perfusion was measured with a DermaTemo Infrared Surface Skin Scanner, a non-invasive high precision hand-held infrared thermographic scanner designed to detect the subtle variations in skin temperature due to changes in the underlying perfusion. Temperature was measured at three standardized anatomic points; values were averaged to calculate the affected to unaffected limb ratio.
Lastly, photographic documentation of skin findings and/or a second assessment by a Pediatric Dermatologist (ILC) were also carried out.
c. Observable veins were measured using the Venous Clinical Severity Score, specifically with the item varicose veins, which also includes corona phlebectatica (45) , and the Vein Prominence Scale (46) . Additional signs related to observable veins were telangiectasias (21) and reticular veins (21) .
d. Limb edema was measured using different methods: 1) limb circumference was measured using a tension-controlled measuring tape (Gulick II, Country Technology Inc., Wisconsin). In children affected by UE DVT, the circumference of the mid-arm of the right and left UE was measured at a distance corresponding to the mid-point between the acromium and olecranon process. In children affected by LE DVT, the circumference of the mid-calf was measured at the mid-point between the tibial tuberosity and the medial malleolus. The mid-thigh circumference was measured at the mid-point between the tibial tuberosity and the anterior superior iliac spine. The absolute difference (in cm) between the affected and unaffected arm or leg, and the ratio of the affected to unaffected arm or leg were estimated. 2) Limb volume was measured by assuming a truncated cone shape of the limb (47) . The volume of four or five truncated cones was added to estimate the volume of the UE and the LE, respectively, based on circumferential measures taken at five anatomic landmarks. Circumferences were measured with a Gulick II tape; the distance between these points (length of the segment) was measured using digital calipers.
The value of the limb volume obtained was normalized by comparing the affected to the unaffected limb, and expressed as a ratio. 3) Ankle size was measured using the Figure- of-8 technique (48) . The difference in cm of the ankle of the affected and unaffected extremities, and the ratio of the affected to unaffected limb were determined. 4) Limb fluid content was measured using a bioimpedance spectrospcopy SFB7 device (Impedimed, Inc. California) (49) (50) (51) , following a pediatric protocol reported previously (52) .
Additional items related to edema were head edema, pretibial edema, and pitting edema (53) . Pretibial and pitting edema were measured by using a 4-point clinical scale (54) and limb durometry (55), estimated with a hand held digital force gauge. This device measures the resistance to tissue compression. Determinations were taken at one specific anatomic location in the extremities; values were averaged to calculate the affected to unaffected limb skin resistance.
e. The functional impact of PTS was assessed as impairments, activity limitation, and participation restrictions (27) according to the framework of the International Classification of Functioning, Disability and Health, Children and Youth Version.
Impairments were evaluated using self-or proxy-reported endurance and strength (56) , as well as testing limb strength with a compact dynamometer (Commander TM muscle tester, JTECH Medical, Utah) in children who were able to comply with the instructions, following a standardized protocol. We determined the affected to unaffected limb strength ratio. Activity limitations and participation restrictions were evaluated with the Pediatric Outcomes Data Collection Instrument (PODCI) (57).
The severity of PTS was determined by a pediatric thrombosis expert (SW, LB) blind
to the results of the measurement procedures mentioned above. PTS was classified as none, mild, moderate and severe, according to the assessors' expert clinical assessment. Given the limitations of the current pediatric tools, neither the Modified Villalta Scale nor the Manco-Johnson
Instrument were used in this study.
Signs and symptoms were measured by study investigators (LA, MM) blind to the PTS severity of the subject. Skin manifestations were also assessed by a pediatric dermatologist (ILC).
Data were entered into a REDCap database. Double-data entry was carried out to ensure accuracy.
2.3.
Sample size: Given the normal difference in hydrostatic pressure between UE and LE, we anticipated a different frequency and/or severity of clinical manifestations of UE and LE-PTS. Therefore, the diagnostic performance of every item was studied separately in UE and LE.
A sample size of 70 subjects per stratum was estimated to produce a two-sided 95% confidence of each item in order to establish their ability to discriminate subjects with and without PTS (i.e., mild, moderate or severe PTS vs. no PTS). The cutoff criterion used for the reported sensitivity and specificity was that corresponding to the Youden index (i.e., the optimal threshold point from the ROC curve). Significance level was set at 0.05.
Statistical analyses were performed using SAS software, version 9.2 (SAS Institute Inc.
Cary, NC, USA) and MedCalc for Windows (MedCalc Software, Ostend, Belgium).
The study was approved by the Research Ethics Boards of The Hospital for Sick Children and of the University of Toronto. Informed consent and assent, when applicable, were obtained.
The instruction letter included in the survey sent to the experts informed them that completion of the survey implied consent.
Results

First phase: Item generation and operationalization
Twenty-five pediatric thrombosis experts were identified and invited to participate in the study; one expert declined participation. The overall complete response rate was 92% (i.e., 23 of the 25 experts completed the survey). The survey was conducted between July-November 2013.
Respondents worked at North-American institutions (n=11), European institutions (n=6),
Australian institutions (n=3), Latin-American institutions (n=2), and Asian institutions (n=1).
Sixteen patients (median age at the time of study enrolment 13. whereas patients listed an average of 3 items each (54 items in total). We analyzed all the listed signs and symptoms to identify similar responses. As a result, we obtained a total of 34 items, which were subsequently grouped according to PTS domains. The number of times each item was proposed (i.e., frequency) per domain is shown in Table 1 .
Experts proposed definitions and/or measurement techniques for some items. For example, the Wong-Baker Faces Pain scale, the Faces Pain Scale, a numerical scale, a Visual analogue scale, or, more generally, the use of "standard or validated scales" were suggested for the measurement of pain. Measurement of edema was the only item mentioned by all the experts who answered the survey. Experts suggested measurement of limb circumference and of limb volume. Some experts considered that >1 centimeter (cm) difference between limbs should be
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14 considered abnormal, whereas others used ≥1 cm, or >1 cm for children <5 years of age and >2 cm for older children. In addition, the use of a variety of anatomical landmarks was proposed. Table 1 also shows the number of definitions and suggested measurement approaches for each item, which were used to develop a set of definitions and measurement techniques (i.e., item operationalization) for the following phase of the study.
In the majority of cases experts suggested the use of a scale but did not specify which.
Therefore, we searched in the literature and contacted experts in the field to find a suitable tool for every item. The diagnostic properties of the items thus defined and characterized were subsequently investigated in the second part of the study. The complete list of definitions and measurement techniques generated is available from the authors upon request.
Second phase: Item piloting
Thirty-two of the 34 items collected were investigated in this part of the study (see discussion for details on the remaining two items), which ran between March 2014 and May
2015.
The characteristics of the enrolled patients are shown in Table 2 .
Throughout the testing of the proxy-version of the symptoms questionnaire, some parents suggested including symptoms that were originally only part of the self-reported version. Hence, the proxy-reported questionnaire was expanded to include optional questions for those nonobservable symptoms.
Items such as pitting edema, pain on palpation, venous claudication, and skin signs (aside from collaterals in UE/LE and varicose veins in LE) were not observed in this cohort of patients.
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The items with strongest correlation with PTS were pain intensity in older children, as per the Faces Pain Scale-Revised and the Adolescent Pediatric Pain Tool, paresthesia and swollen limb for the UE stratum, and pain intensity, as per the Adolescent Pediatric Pain Tool, tired limb, heaviness, paresthesia, tightness and endurance for the LE stratum (Tables 3 and 4 ).
The items with largest AUCs were pain in older children, as per the Faces Pain ScaleRevised and Adolescent Pediatric Pain Tool, tired limb, paresthesia, and observable veins. In the LE stratum, the best performing items were pain (measured by the Adolescent Pediatric Pain Tool), heaviness, tightness, thigh circumference difference and ratio, and Pediatric Outcomes Data Collection Instrument (Tables 3 and 4 ).
Overall, items had higher specificity than sensitivity.
Discussion
In this report we present the first steps of the development of a new tool for the discrimination and evaluation of pediatric PTS affecting the UE and LE.
We considered that the theory underlying the formative model was appropriate to study our construct. As a consequence, we first elicited the signs and symptoms of PTS from a group of experts and affected patients.
The items most commonly endorsed by both patients and experts were pain and edema, which are items included in the tools developed to measure PTS in adults (16, 58, 59 ) and children, and are the only items of the Ginsberg criteria for the diagnosis of PTS in adult patients (59) .
Experts also proposed several additional symptoms, including for example heaviness and pruritus, which contrast with the fact that the Modified Villalta Scale and Manco-Johnson Instrument only assess one or two symptoms. The limited number of symptoms that the
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Modified Villalta Scale and Manco-Johnson Instrument assess in comparison with the Villalta Scale, which has been acknowledged (15) , roots on the difficulty of measuring symptoms in young patients. Still, when tailored to the age of the patient, the measurement of symptoms provided valuable information. In fact, the best performing items in the item-piloting phase of the study were pain (as measured in older children) and other symptoms, such as paresthesia for the UE and heaviness and tightness for the LE.
Patients in the LE stratum reported a higher frequency of symptoms than the patients on the UE stratum, and diagnostic properties of the symptoms differed between UE and LE. Overall, LE symptoms showed better diagnostic properties than UE symptoms. These facts suggest the need for evaluating UE and LE differently, using tailored tools. Indeed, the severity and frequency of clinical manifestations of UE and LE PTS are expected to differ. Moreover, clinical signs that usually present later during the natural course of LE PTS (e.g., varicose veins, hyperpigmentation, skin ulcers) may not be seen in UE PTS. A potential unwanted effect of using the same tool for assessment of both the upper and lower venous territory is that most children will likely have low scores when assessing UE PTS, leading to floor effects (60) . If patients with UE PTS are less symptomatic and cluster on the lower end of a tool, then the tool will have a low discriminatory power, which will affect its sensitivity and responsiveness (61) .
The responsiveness of the tool is relevant to monitor patients over time, and to assess the efficacy of interventions.
Several items, including skin manifestations (pigmentation, inflammation, induration, ulcers), pain on palpation, pitting edema, and venous claudication were not observed in this study, which is probably due to the relatively milder nature of PTS manifestations in children, as compared to adults. In addition, five of the nine signs of the Modified Villalta Scale and two of the four signs of the Manco-Johnson Instrument were not seen in our patients, suggesting their infrequent occurrence and potential problem with floor effects when applying these tools. These findings suggest that the new pediatric PTS tool currently being developed may be simpler than the current tools, at least in terms of clinical signs.
In general, individual items were more specific than sensitive. This is likely due to the fact that PTS is a syndrome composed of signs and symptoms, and the combination of items is expected to be more useful for the determining the presence or absence of PTS than any sign or symptom by itself (62) . With the probable exception of limb swelling, no single sign or symptom is a common denominator of PTS. In fact, limb swelling was the only item proposed by all the experts in the first part of the study, and was also the most sensitive in both strata. Symptoms, on the other hand, are harder to identify as younger patients may not recognize or express them.
Our results should be interpreted in the light of possible study limitations. For example, the reliance on clinical expertise to define PTS instead of the existing tools may be debatable.
However, this was necessary to overcome the problems with the existing instruments. Since PTS is a syndrome essentially diagnosed on clinical grounds (12) , and no test has been able to replace clinical assessment in establishing the presence or absence of PTS, the evaluation of the patients enrolled in our study only by experienced clinicians was considered the best approach for determination of PTS severity. This approach was also consistent with the theory behind the formative model. In addition, patients were assessed by one of the clinical experts, as assessment of the entire group of patients by both experts was not feasible in the context of the study.
It must be pointed out that quality of life and loss of venous access were not included among the measured items. The International Classification of Functioning, Disability and Health, Children and Youth Version acknowledges that the concepts of quality of life and
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18 disease/disability are related. However, whereas quality of life pertains to how patients "feel" about their health, disease/disability refers to "objective and exteriorized signs of the individual" (27) . In consequence, quality of life was considered to be outside the framework of our study.
Nonetheless, we assessed two other more closely related components of functioning, namely activity and participation, using the Pediatric Outcomes Data Collection Instrument (57) . The measurement of loss of venous access was deemed not directly assessable in the clinical setting and was not included in the present work.
In conclusion, these two steps identified the signs and symptoms that experts and patients consider that should be used to assess and monitor pediatric PTS. Each sign and symptom differed in its strength of association with PTS severity, as well as its diagnostic properties, when assessing the UE vs. the LE, or younger vs. older patients (as in the case of pain assessment).
This information is not only relevant to the following steps of the tool development, but also a thought provoking analysis of the measurement theory and practice of pediatric PTS. The following steps comprise the selection of the items to be included in the tool and the development of a weighting scheme for the items that allows an overall interpretation of scores consistent with the measurement approach followed herein. 
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